Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
© 2023. The Author(s)..
Many clinical trial results are available to inform best practices in the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD).Herein, we summarize the results of clinical trials, including patient-reported outcome instruments, for the treatment of patients with ILD associated with systemic sclerosis (SSc/scleroderma), rheumatoid arthritis, and idiopathic inflammatory myositis, the diseases with the most available data. For SSc-ILD, the US Food and Drug Administration approved nintedanib (a tyrosine kinase inhibitor) in 2020 and subcutaneous tocilizumab (an IL-6 receptor monoclonal antibody) in 2021. Rituximab was recently shown to have similar efficacy but better tolerability than intravenous cyclophosphamide (CYC) for CTD-ILD therapy. Scleroderma Lung Study II, conducted in patients with SSc-ILD, showed that oral CYC and mycophenolate mofetil (MMF) were comparable in their effects on lung function, but MMF was better tolerated. The increasing treatment armamentarium for patients with CTD-ILD offers physicians new opportunities to improve patient outcomes.
| Errataetall: |
ErratumIn: Arthritis Res Ther. 2023 Jul 27;25(1):132. - PMID 37501068 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Arthritis research & therapy - 25(2023), 1 vom: 08. Juli, Seite 118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Higuero Sevilla, Jean Paul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.07.2023 Date Revised 12.03.2024 published: Electronic ErratumIn: Arthritis Res Ther. 2023 Jul 27;25(1):132. - PMID 37501068 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13075-023-03090-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359237045 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359237045 | ||
| 003 | DE-627 | ||
| 005 | 20240312233117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-023-03090-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM359237045 | ||
| 035 | |a (NLM)37422652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Higuero Sevilla, Jean Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Arthritis Res Ther. 2023 Jul 27;25(1):132. - PMID 37501068 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Many clinical trial results are available to inform best practices in the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD).Herein, we summarize the results of clinical trials, including patient-reported outcome instruments, for the treatment of patients with ILD associated with systemic sclerosis (SSc/scleroderma), rheumatoid arthritis, and idiopathic inflammatory myositis, the diseases with the most available data. For SSc-ILD, the US Food and Drug Administration approved nintedanib (a tyrosine kinase inhibitor) in 2020 and subcutaneous tocilizumab (an IL-6 receptor monoclonal antibody) in 2021. Rituximab was recently shown to have similar efficacy but better tolerability than intravenous cyclophosphamide (CYC) for CTD-ILD therapy. Scleroderma Lung Study II, conducted in patients with SSc-ILD, showed that oral CYC and mycophenolate mofetil (MMF) were comparable in their effects on lung function, but MMF was better tolerated. The increasing treatment armamentarium for patients with CTD-ILD offers physicians new opportunities to improve patient outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Connective tissue disease | |
| 650 | 4 | |a Fibrotic lung disease | |
| 650 | 4 | |a Inflammatory lung disease | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Nintedanib | |
| 650 | 4 | |a Pirfenidone | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Scleroderma | |
| 650 | 4 | |a Systemic sclerosis | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 700 | 1 | |a Memon, Areeka |e verfasserin |4 aut | |
| 700 | 1 | |a Hinchcliff, Monique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 25(2023), 1 vom: 08. Juli, Seite 118 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:08 |g month:07 |g pages:118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-023-03090-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 08 |c 07 |h 118 | ||